The gene amplification, overexpression, and activation of YES1 have been observed in trastuzumab-resistant HER2-positive breast cancer cells (BR-474-R) and trastuzumab/lapatinib-dual-resistant BT-474-RL2 cells. Here, YES1 is linked to breast carcinoma.